The ATXN1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the human A-549 cell line, featuring targeted disruption of the ATXN1 gene. This polyclonal population provides a physiologically relevant loss-of-function model for studying ataxin-1 biology, as it recapitulates the genetic heterogeneity inherent to a knockout pool derived from multiple editing events without single-cell clonal selection.
The host A-549 cell line is a widely used cellular model derived from human lung adenocarcinoma, exhibiting characteristics of alveolar type II epithelial cells. These adherent epithelial cells are well characterized in cancer biology, drug metabolism, and toxicology studies. Their robust growth and well-established culture conditions make them a convenient and reproducible platform for genetic manipulation, enabling the investigation of gene function in a lung cancer context.
ATXN1 encodes ataxin-1, a polyglutamine-containing protein that functions primarily in transcriptional regulation and RNA metabolism. Ataxin-1 forms a transcriptional repressor complex with the capicua (CIC) transcription factor, a critical interaction that modulates the expression of a wide array of target genes involved in development and neurological function. Activity of the ATXN1?CCIC complex is influenced by several upstream regulators, including the Notch intracellular domain, AKT, and MAP kinases, which mediate phosphorylation-dependent modulation of ataxin-1 stability and complex formation. Downstream targets of this repressor complex include axin-1 and tau, linking ATXN1 to Wnt signaling and cytoskeletal regulation. Additionally, ATXN1 interacts with its paralog ATXN1L, RNA-binding proteins, and other transcription factors, underscoring its multifunctional role in coordinating gene expression programs.
In the A-549 lung adenocarcinoma background, disruption of ATXN1 is predicted to perturb the ATXN1?CCIC transcriptional repressor axis, potentially leading to dysregulated expression of genes involved in cell proliferation, differentiation, and survival. Given the well-documented crosstalk between ATXN1 and Notch signaling, knockout of ATXN1 in this epithelial cancer model may alter Notch-responsive transcriptional programs that influence tumor cell behavior. This polyclonal knockout population thus offers a valuable tool for dissecting the contribution of ataxin-1 to lung cancer biology, including studies of tumor growth, epithelial?Cmesenchymal transition, and response to therapeutic agents.
This knockout cell model is suited for a range of research applications, such as investigating the molecular pathogenesis of spinocerebellar ataxia type 1 (SCA1), elucidating ATXN1-dependent transcriptional regulatory networks, and exploring its role in cancer. Representative assays include western blotting and RT-qPCR for assessing target gene expression, co-immunoprecipitation for studying protein?Cprotein interactions, immunofluorescence for subcellular localization, and cell proliferation assays for functional phenotyping. Additionally, the cells can be employed in high-throughput drug screening to identify modulators of ATXN1-related pathways. For further information or to discuss customization options, please contact Ascent Research.
